41
Participants
Start Date
July 31, 2006
Primary Completion Date
June 30, 2009
Study Completion Date
June 30, 2009
Iloprost (Ventavis BAYQ6256)
Patients with pulmonary arterial hypertension, classified as New York Heart Association functional class III or IV where the treating physician has chosen Ventavis as a suitable treatment prior to inclusion into this non-interventional study. Patients should not have received prior treatment with Ventavis
Many Locations
Lead Sponsor
Bayer
INDUSTRY